Showing results (151-160 of 207) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|January 30, 2026
Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint developmentAlex Lepak, Sujata M Bhavnani, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|November 27, 2013
Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniaeScott A Van Wart, Paul G Ambrose, Christopher M Rubino, et al.
Antimicrobial Agents and Chemotherapy|March 14, 2023
Evaluation of the Impact of Comorbidities on Omadacycline PharmacokineticsM Trang, E A Lakota, M C Safir, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2009
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infectionOlanrewaju O Okusanya, Sujata M Bhavnani, Jeffrey Hammel, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2007
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulationChristopher M Rubino, Lei Ma, Sujata M Bhavnani, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2014
Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection modelBrian D VanScoy, Rodrigo E Mendes, Mariana Castanheira, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2024
Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infectionsSujata M Bhavnani, Jeffrey P Hammel, Elizabeth A Lakota, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2011
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemiaDavid Andes, Paul G Ambrose, Jeffrey P Hammel, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2019
Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumoniaSujata M Bhavnani, Li Zhang, Jeffrey P Hammel, et al.
Antimicrobial Agents and Chemotherapy|March 22, 2023
Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric ApproachesA J Lepak, M Trang, J P Hammel, et al.
Pageof 21